Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
20

Inclusion Criterias

Age ≥18 years.
Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.
Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.
...
Age ≥18 years.
Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.
Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.
Deemed eligible for ASCT by standard institutional criteria.
Documentation of CT7, MAGE-A3, or WT1 expression in the bone marrow and/or bone marrow aspirate.

Exclusion Criterias

Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.
Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.
Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.
...
Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.
Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.
Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.
Prior autologous or allogeneic SCT.
History of autoimmune disease (e.g., rheumatoid arthritis, SLE), other than vitiligo, diabetes, or treated thyroiditis, which are allowed.
History of severe allergic reactions to vaccines or unknown allergens.
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.

Summary

Conditions
Multiple Myeloma
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criterias

Age ≥18 years.
Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.
Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.
...
Age ≥18 years.
Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.
Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.
Deemed eligible for ASCT by standard institutional criteria.
Documentation of CT7, MAGE-A3, or WT1 expression in the bone marrow and/or bone marrow aspirate.

Exclusion Criterias

Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.
Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.
Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.
...
Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.
Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.
Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.
Prior autologous or allogeneic SCT.
History of autoimmune disease (e.g., rheumatoid arthritis, SLE), other than vitiligo, diabetes, or treated thyroiditis, which are allowed.
History of severe allergic reactions to vaccines or unknown allergens.
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.

Locations

New York, New York, 10065
New York, New York, 10065

Tracking Information

NCT #
NCT01995708
Collaborators
Not Provided
Investigators
  • Principal Investigator: David Chung, MD, PhD Memorial Sloan Kettering Cancer Center
  • David Chung, MD, PhD Memorial Sloan Kettering Cancer Center